Descripciones mejoradas de Syndetics:

Striving for intensive diabetes management is now the rule, rather than the exception, in diabetes care. Virtually all patients with diabetes -- type 1 or type 2 -- can improve their glyceic control and overall health through intensive diabetes management. With emphasis on the team approach, this hands-on book offers the information you need to help each patient move toward treatment goals appropriate for their individual skills and medical condition. For clinicians striving to deliver diabetes therapy for the 21st century, this book is the essential guide. Book jacket.

Tabla de contenidos provista por Syndetics

• A Word About This Guide(p. ix)
• Contributors to the Third Edition(p. xi)
• Acknowledgments(p. xiii)
• Terminology of Intensive Diabetes Management(p. xiv)
• Rationale for and Physiological Basis of Intensive Diabetes Management(p. 1)
• Highlights(p. 2)
• Intensive Diabetes Management(p. 4)
• Physiological Basis of Intensive Management Methods(p. 6)
• Normal Fuel Metabolism(p. 6)
• Regulation of Fuel Metabolism(p. 8)
• Implications for Therapy(p. 9)
• The Team Approach(p. 13)
• Highlights(p. 14)
• Concept of Team Management(p. 15)
• Integrated Diabetes Management Team(p. 17)
• Role Definition(p. 19)
• Team Communication(p. 21)
• Functional Considerations(p. 21)
• Diabetes Self-Management Education(p. 25)
• Highlights(p. 26)
• Integration of the Team Approach(p. 27)
• Diabetes Continuing Education(p. 27)
• Assessment(p. 28)
• Instruction(p. 29)
• Environment(p. 29)
• Planning(p. 30)
• Content(p. 30)
• Sequencing of Classes(p. 31)
• Approaches/Strategies(p. 31)
• Motivation(p. 33)
• Negotiation(p. 33)
• Evaluation(p. 34)
• Documentation(p. 34)
• Conclusion(p. 35)
• Psychosocial Issues(p. 37)
• Highlights(p. 38)
• Assessing Patient Suitability for Intensification(p. 40)
• Practicing Behavior(p. 40)
• Assessing Psychological Status and the Psychosocial Support System(p. 41)
• The Family System(p. 42)
• The Individual(p. 43)
• Assessing the Effect of Stress on Glycemic Control(p. 44)
• Assessing Coping Skills(p. 46)
• Assessment of Diabetes-Related Coping(p. 46)
• Identifying Psychosocial Resources(p. 46)
• Helping Patients Deal with Complications(p. 47)
• Potential Adverse Psychological Outcomes of Treatment(p. 48)
• Eating and Body Image Disorders(p. 48)
• Fear of Hypoglycemia(p. 49)
• Needle Phobia(p. 50)
• Helping Patients with Long-Term Adherence(p. 51)
• Supporting and Maintaining Patients' Behavior Changes(p. 52)
• Helping Patients with New Therapies(p. 53)
• Acceptance of Multiple Therapies(p. 54)
• Lifestyle Changes(p. 54)
• Conclusion(p. 57)
• Patient Selection and Goals of Therapy(p. 59)
• Highlights(p. 60)
• Patient Selection(p. 61)
• Patients with Type 1 Diabetes(p. 63)
• Patients with Type 2 Diabetes(p. 64)
• Goals of Therapy(p. 65)
• Glycemic Goals(p. 67)
• Modifying Glycemic Goals(p. 68)
• Weighing Benefits and Risks in Type 2 Diabetes(p. 69)
• Conclusion(p. 69)
• Multiple-Component Insulin Regimens(p. 73)
• Highlights(p. 74)
• Insulin Pharmacology(p. 76)
• Insulin Timing and Action(p. 76)
• Stability and Miscibility of Insulins(p. 78)
• Insulin Absorption(p. 79)
• Insulin Regimens(p. 80)
• Multiple-Component Insulin Regimens: General Points(p. 80)
• Specific Flexible Multiple-Component Insulin Regimens(p. 82)
• Other Insulin Programs(p. 86)
• Insulin Dose and Distribution(p. 89)
• Initial Insulin Doses(p. 89)
• Insulin Dose Distribution(p. 90)
• Insulin Adjustments(p. 91)
• Acute Adjustments(p. 91)
• Pattern Adjustments(p. 92)
• Injection Devices(p. 96)
• Conclusion(p. 96)
• Insulin Infusion Pump Therapy(p. 99)
• Highlights(p. 100)
• Benefits of CSII(p. 104)
• Insulin Dosage Calculations for Insulin Pump Therapy(p. 105)
• Insulin Adjustments(p. 108)
• Diet(p. 108)
• Exercise(p. 108)
• Illness(p. 109)
• Correction of Hyperglycemia(p. 109)
• Risks of CSII(p. 109)
• Skin Infection(p. 109)
• Unexplained Hyperglycemia and Ketoacidosis(p. 110)
• Hypoglycemia(p. 112)
• Wearing the Pump(p. 113)
• Patient Education for CSII(p. 114)
• Implantable Insulin Infusion Pumps(p. 117)
• Monitoring(p. 121)
• Highlights(p. 122)
• Monitoring by the Patient(p. 123)
• Blood Glucose(p. 123)
• Ketone Monitoring(p. 125)
• Record Keeping(p. 126)
• Monitoring by the Health Care Team(p. 127)
• A1C(p. 127)
• Hypoglycemia(p. 128)
• Prevention(p. 128)
• Hypoglycemia Unawareness(p. 130)
• Continuous Glucose Monitoring(p. 130)
• Monitoring for Long-Term Complications(p. 131)
• Retinal Examinations(p. 131)
• Lipid Screening(p. 132)
• Blood Pressure(p. 132)
• Urinary Albumin Screening(p. 133)
• Foot Examinations(p. 133)
• Nutrition Management(p. 135)
• Highlights(p. 136)
• Goals of MNT(p. 138)
• Target Nutrition Recommendations(p. 139)
• Strategies for Type 1 Diabetes(p. 141)
• Strategies for Type 2 Diabetes(p. 143)
• Glucose Monitoring and the Nutritional Plan(p. 145)
• Hypoglycemia(p. 145)
• Skipping or Delaying Planned Meals or Snacks(p. 145)
• Inappropriate Timing of Insulin Relative to Meals(p. 147)
• Imbalance Between Food and Meal-Related Insulin Dose(p. 148)
• Inadequate Food Supplementation for Exercise(p. 148)
• Consuming Alcohol on an Empty Stomach(p. 149)
• Oral Treatment of Hypoglycemia(p. 150)
• Facilitating Nutrition Self-Management(p. 150)
• Meal-Planning Approaches for Intensified Management(p. 151)
• Carbohydrate Counting(p. 151)
• Weight Gain Associated with Intensive Management(p. 153)
• Prevention(p. 153)
• Index(p. 157)

Notas de autor provistas por Syndetics

Georgeanna J. Klingensmith, MD, is a Professor of Pediatrics at the University of Colorado School of Medicine and Director of Pediatric Diabetes Services at the Barbara Davis Center for Childhood Diabetes and The Children's Hospital in Denver. A pediatric endocrinologist, Dr. Klingensmith has expertise in the epidemiology of diabetes and diabetes autoimmunity in children, the psychological impact on families of the identification of infants at very high risk for diabetes, and the exploration of new therapies for children with type 1 diabetes. She is an investigator on an NIH-funded multicenter study evaluating treatment modalities in type 2 diabetes in children, as well as a CDC-funded, NIH-supported study to define the incidence and prevalence of diabetes in children and adolescents.